Cressey T. auteur aut IRD Van Dyke R. auteur aut IRD Jourdain Gonzague auteur aut IRD Puthanakit T. auteur aut IRD Roongpisuthipong A. auteur aut IRD Achalapong J. auteur aut IRD Yuthavisuthi P. auteur aut IRD Prommas S. auteur aut IRD Chotivanich N. auteur aut IRD Maupin R. auteur aut IRD Smith E. auteur aut IRD Shapiro D. E. auteur aut IRD Mirochnick M. auteur aut IRD text journalArticle eng text/pdf born digital access Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) mu g.h/ml, 11.2 (8.0 to 17.5) mu g/ml, and 4.6 (1.7 to 12.5) mu g/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported. specialized THAILANDE 052 050 53 5 2189-2191 2009 0066-4804 https://www.documentation.ird.fr/hor/PAR00003512 10.1128/aac.01091-08 0066-4804 [F B010089807] https://www.documentation.ird.fr/hor/PAR00003512 https://www.documentation.ird.fr/intranet/publi/2024-04/010089807.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2009-06-08 2024-04-24 PAR00003512 fre